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Over 50% of HIV-1/AIDS patients suffer chronic pain. Currently, opioids are the
cornerstone medications for treating severe pain in these patients. Ironically, emerging
clinical data indicates that repeated use of opiate pain medicines might in fact heighten
the chronic pain states in HIV patients. Both laboratory-based and clinical studies
strongly suggest that opioids exacerbate the detrimental effects of HIV-1 infection on
the nervous system, both on neurons and glia. The combination of opioids and HIV-
1infection may promote the damage of neurons, including those in the pain sensory
and transmission pathway, by activating both caspase-dependent and caspase-
independent pro-apoptotic pathways. In addition, the opiate-HIV-1 interaction may also
cause widespread disturbance of glial function and elicit glial-derived pro-inflammatory
responses that dysregulate neuronal function. The deregulation of neuron-glia cross-talk
that occurs with the combination of HIV-1 and opioids appears to play an important role
in the development of the pathological pain state. In this article, we wish to provide
an overview of the potential molecular and cellular mechanisms by which opioids
may interact with HIV-1 to cause neurological problems, especially in the context
of HIV-associated pathological pain. Elucidating the underlying mechanisms will help
researchers and clinicians to understand how chronic use of opioids for analgesia
enhances HIV-associated pain. It will also assist in optimizing therapeutic approaches to
prevent or minimize this significant side effect of opiate analgesics in pain management
for HIV patients.
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INTRODUCTION
Pathological pain is a major neurological complication suffered by over 50% of HIV-1/AIDS
patients (Hewitt et al., 1997; Mirsattari et al., 1999; Evers et al., 2000). Patients with HIV-associated
pain syndromes may suffer headache, somatic pain, and visceral pain (Hewitt et al., 1997; Mirsattari
et al., 1999; Evers et al., 2000; Aouizerat et al., 2010). The pain is typically bilateral, of gradual
onset and described as ‘aching,’ ‘painful numbness,’ or ‘burnings’ (Cornblath and McArthur,
1988). However, the molecular and cellular processes by which HIV patients develop pain remain
elusive. Pathologically, about 30% of HIV-1/AIDS patients with pain symptoms manifest clinically
detectable peripheral neuropathy (Martin et al., 2003). Although highly active antiretroviral
therapy (HAART) has dramatically reduced the morbidity and mortality of HIV-1 infection
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(Mocroft et al., 2003), patients on HAART still develop symptoms
of distally symmetric small-fiber retrograde axonal neuropathy
and pain (Simpson, 2002; Luciano et al., 2003; Lopez et al., 2004;
Arenas-Pinto et al., 2008). Previous studies indicate that gp120
can induce cutaneous denervation in the transgenic mouse model
(Keswani et al., 2006), intrathecal injection model (Milligan et al.,
2001; Yuan et al., 2014), and in the sciatic nerve exposure model
(Wallace et al., 2007a,b). Gp120 can also cause axonal injury
of sensory neurons in culture (Melli et al., 2006; Hoke et al.,
2009).
Controlling pain is a big challenge in HIV patient care.
The clinical practice for pain management in HIV patients
has been recommended to follow the WHO guideline (World
Health Organization, 1996; Basu et al., 2007). According to the
guideline, opioids are the cornerstone medications for treating
moderate to severe pain. Ironically, besides the powerful acute
analgesic effect, emerging clinical data indicate that repeated
use of opioid analgesics promotes chronic pain in HIV patients
(Smith, 2011; Onen et al., 2012). Studies on simian or simian-
human immunodeficiency virus-infected monkey models suggest
a role of opioids in HIV-related disease progression (Kumar et al.,
2004, 2006; Rivera-Amill et al., 2010). HIV-1-infected opioid
abusers also appear to show more severe neuropathology than
HIV-1-infected non-drug users (Bell et al., 1998, 2006; Anthony
et al., 2005, 2008). Currently, the mechanisms by which opioid
medicines exacerbate HIV- associated pain are unclear. Multiple
molecular systems in neurons, including mu-opioid receptors,
N-methyl-D-aspartate receptors, nitric oxide synthase, heme
oxygenase, 5-hydroxytryptamine type 3 receptors, complement
components, chemokines and the melanocortin system have been
implicated in opiate-induced hyperalgesia (Basu et al., 2007), but
whether (and how) they contribute to the exacerbation of HIV-
associated pain is unclear. Opioids can also activate glial cells such
as microglia and astrocytes (Tortorici et al., 1999; Song and Zhao,
2001; Raghavendra et al., 2002; Mika, 2008; Horvath and DeLeo,
2009; Mika et al., 2009; Lee et al., 2011), which may facilitate the
expression of hyperalgesia by releasing various neural regulators
such as cytokines, chemokines and brain-derived neurotrophic
factor to induce sensitization of pain-processing neurons (Hao,
2013).
Although we have a significant understanding of the potential
mechanisms by which HIV-1 infection (including antiretroviral
therapy) and opioid use induce pain individually, little is
known about how their interaction would contribute to
pain pathogenesis. We will consider the potential pathogenic
mechanisms from the perspective of neuron-glial crosstalk.
In the following sections, we will first provide overviews of
the detrimental effects of HIV-1 and opioids, separately or
combinatorially, on neurons and glia. Based on these findings, we
will discuss the possible pathogenic processes induced by HIV-
1 and opioids that facilitate the development of HIV-associated
pain. We regret that due to limited space we cannot cover all of
the significant work in this field but are forced to focus on selected
findings to illustrate our views. The purpose of this paper is not
to provide a systematic review of current literature. Instead, we
aim to provide mechanistic viewpoints on how HIV-1 infection
might interact with opioids to promote pain pathologies.
NEURONAL MECHANISMS
We postulate that neuronal damage is a major mechanism
by which interaction of HIV-1 and opioids facilitates the
development of hyperalgesia. Here, we will first discuss how
nerve damage can lead to the expression of pathological pain and
then how gp120 and opioids may cause neuronal damage.
Damage of peripheral or central pain transmission neurons,
manifested by hyper-excitability and/or a lowered threshold
of activation, directly contributes to neuropathic pain (Baron,
2000; Treede et al., 2008). Pathological pain in HIV patients
is frequently associated with peripheral sensory neuropathy,
a form of the so-called ‘dying-back’ degeneration of sensory
neurons (Hao, 2013). Sensory neuropathy also develops in
various animal models of HIV-associated pain, including rodents
models generated by exposure of peripheral nerves or spinal cord
to gp120 (Herzberg and Sagen, 2001), gp120 transgenic mice
receiving antiretroviral drugs (Keswani et al., 2006) and SIV-
infected monkeys (Hou et al., 2011). Thus, neuronal damage is
intimately associated with the expression of HIV-associated pain.
Many events such as neuronal hyper-excitation, inflammation
and viral infection can cause nerve damage that leads to
neuropathic pain (Woolf and Mannion, 1999). Neuropathic pain-
related damage may lead to neuronal apoptosis via caspase-
dependent and -independent pathways (Perl and Banki, 2000; Oh
et al., 2001; Gougeon, 2003; Silva et al., 2003). Using HIV-1 gp120
protein as an example, we will describe how HIV-1 infection
may interact with opioids to promote these pathways in pain-
processing neurons.
Damage of peripheral nerves may contribute to pain
pathogenesis via various pathways. For instance, when peripheral
nervesare damaged, sodium-channels may aggregate locally
and/or in cell bodies, which may lead to hyper excitability
(Lai et al., 2003; Wood et al., 2004). Ectopic expression of
specific calcium channels on DRG cells has also been observed
following neuronal damage (Luo et al., 2001). The nerve-damage-
induced changes of ion channel expression may be intimately
linked to peripheral sensitization. In addition to ion channels,
neuronal damage induces the ectopic expression of specific
pain sensory receptors such as TRPV1, a vanilloid receptor for
thermal sensation. TRPV1 is normally expressed on nociceptive
afferent fibers. When nerve damage occurs, TRPV1 expression
decreases on injured afferents and increases on undamaged
Cfibers and Aδfibers (Hudson et al., 2001; Hong and Wiley,
2005). Nerve-damage-induced increases of other pain-related
factors, including acid-sensing ion channels (ASICs; Price et al.,
2001), adrenoceptors in neurons (Price et al., 1998; Baron et al.,
1999) and pro-inflammatory cytokines (e.g., TNF-α; Marchand
et al., 2005) in glial cells,have also been implicated in peripheral
sensitization.
The sensitization of primary afferent nerves can facilitate
the expression of central sensitization of CNS pain-processing
neurons in the spinal cord dorsal horn and supraspinal regions
(Price, 2000; Zhuo, 2002). Peripheral nerve damage can lead to
the activation of excitatory glutamate receptors such as NMDARs
and AMPARs in spinal neurons (Miller et al., 2011). In addition,
damage to peripheral nerves also causes reduced expression and
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uptake activity of both neuronal and glial glutamate transporters,
which may contribute to increased neuronal excitability (Sung
et al., 2003); these effects are mediated by the activation of
PKC and MAPK signaling pathways (Malmberg et al., 1997;
Ji and Woolf, 2001). Furthermore, hyperactivation of Cfibers
induces ectopic expression of sodium channels (Hains et al.,
2004) and calcium channels (Luo et al., 2001) on dorsal
horn neurons to facilitate pain transmission. Malfunction of
inhibitory mechanisms may also facilitate central sensitization.
Peripheral nerve damage can induce the apoptosis of GABA
(γ-aminobutyricacid) inhibitory neurons in superficial layers
of the dorsal horn (Moore et al., 2002; Coull et al., 2003).
Several studies suggest an association of neuronal apoptosis
with neuropathic pain (Mao et al., 2002a; Moore et al.,
2002; Campana and Myers, 2003; Schmeichel et al., 2003),
and inhibition of apoptosis decreases the pain behaviors
(Joseph and Levine, 2004; Scholz et al., 2005; Sekiguchi et al.,
2009).
HIV-1 does not infect neurons (Lipton, 1998; Michaels
et al., 1988). However, HIV-1 infection of the nervous system,
especially of microglia and astrocytes, can cause neuronal damage
and apoptosis via toxic viral proteins that are secreted from
infected cells. Glycoprotein 120 (gp120), the viral envelope
protein that mediates HIV infection, is one of the secreted HIV-1
proteins that causes neuronal dysfunction (Michaels et al., 1988;
Nath, 2002). Our recent analysis on HIV patient tissues and
mouse models suggests a crucial role of gp120 in the pathogenesis
of HIV-associated pain (Yuan et al., 2014). Gp120 may induce
neurotoxicity either by directly stimulating neurons (“direct
injury”) or indirectly by activating glial cells (“bystander effect”;
Kaul et al., 2001). For instance, gp120 activates C-X-C chemokine
receptor 4 (CXCR4), which is constitutively expressed on DRG
and spinal cord neurons (Oh et al., 2001; Miller et al., 2009), and
up-regulates C-C chemokine receptor 2 (CCR2) in a calcium-
dependent manner to produce neurotoxicity (Hesselgesser et al.,
1997; Jung and Miller, 2008). It has been suggested that
gp120-induced neuronal CXCR4 activation may up-regulate pro-
inflammatory cytokine IL-1β in a neuronal autocrine fashion,
which then causes the neuronal excitotoxicity (Bagetta et al.,
1999; Corasaniti et al., 2001a,b). In addition, gp120 is known
to stimulate CXCR4 on DRG satellite glia and induce the
secretion of RANTES (Regulated on Activation, Normal T
cell Expressed and Secreted) chemokine (a.k.a. CCL5), which
induces neuronal damage by activating CCR5 receptors on DRG
neurons (Hesselgesser et al., 1997; Oh et al., 2001). Glutamate
receptors (Mattson et al., 2005), especially NMDA receptors
(Lipton et al., 1991; Lipton, 1992; Bennett et al., 1995; Lannuzel
et al., 1995; Meucci and Miller, 1996; Chen et al., 2005), are
targets of gp120, and their over-activation by gp120 can cause
neurotoxicity.
There are three apoptotic pathways: caspase-dependent
extrinsic (also known as death receptor approach) and intrinsic
(known as mitochondrial approach) pathways (Sinkovics, 1991)
as well as a caspase-independent pathway that is T cell-mediated
and exhibits perforin-granzyme-dependent apoptosis (Elmore,
2007). Gp120 can induce neuronal apoptosis via the extrinsic
and intrinsic pathways (Bagetta et al., 1999; Chen et al., 2005,
2011a; Singh et al., 2005). In the extrinsic pathway, TNF-
α secreted by gp120-activated glial cells can bind to TNF-α
receptor 1 on neurons and induce neuronal apoptosis. Gp120
also can bind to CXCR4 on neurons to induce apoptosis by
promotingcalcium influx and glutamate uptake (Hesselgesser
et al., 1998). In the intrinsic pathway, gp120 is able to increase the
expression and phosphorylation of p53 and subsequently induce
the disruption of the mitochondrial membrane by activating
BCL-2-associated X protein (Bax; Gougeon, 2003). Interestingly,
accumulation ofp53 has been observed in the neurons of AIDS
patients (Silva et al., 2003). Gp120 also can activate phospholipase
A2 and increase the release of arachidonic acid to disrupt
glutamate metabolism in neurons via NMDA-receptor-mediated
neurotoxicity, which can lead to cell dysfunction or death
(Ushijima et al., 1995).
Mounting evidence indicates that chronic opiate use
exacerbates the neuronal damage induced by HIV proteins
gp120 and tat through synergy of neuronal apoptosis (Gurwell
et al., 2001; Hu et al., 2005) and alteration of dendritic spines and
dendrites (Fitting et al., 2010). Ion channels have been implicated
in the synergic neurotoxic effects of opioids and gp120. Gp120
can induce K+ eﬄux by activating K channels when it binds to
CXCR4 (Chen et al., 2011a). Chronic administration of opioids
can reduce K+ inflow by down-regulating MOR (Christie,
2008). Thus, dysfunction of K+ channels may contribute to
neurotoxicity and may be a point of convergence for gp120-
opioid synergism of chronic pain (Podhaizer et al., 2012).
In addition, chemokine receptors can dimerize with MOR,
implying a functional interaction between these receptors (Toth
et al., 2004). In this context, CXCR4 and CCR5 are particularly
interesting because they not only are co-receptors of gp120 but
are also co-expressed with MOR on neurons (Sengupta et al.,
2009; Heinisch et al., 2011). Besides synergism in neurons, gp120
and opioids may also functionally interact in glia to indirectly
facilitate neuronal damage by regulating chemokines (Mahajan
et al., 2005) and glutamate uptake (Podhaizer et al., 2012), which
is the focus of a later section.
When gp120 and/or chronic opioids cause damage to pain-
processing neurons, they may induce neuropathic pain. Gp120
not only directly excites rat DRG neurons and induces allodynia
by activating their chemokine receptors (Oh et al., 2001) but
also mediates local axonal degeneration of cultured rodent
DRG neurons, which is dependent on activation of the caspase
pathways (Melli et al., 2006). By a similar mechanism, exposure
to gp120 also leads to up-regulation of MCP-1 and CCR2 on
DRG neurons and upregulation of their activation, which is
expected to contribute to neuropathic pain (Miller et al., 2009).
We have generated a gp120 neuropathic pain model that develops
similar neuropathologies as human HIV patients, including
peripheral neuropathy and synapse degeneration (Yuan et al.,
2014).
Accumulating data indicate that glial-neuronal cross-talk
plays an important role in opioid-abuse-induced paradoxical
pain (Raghavendra et al., 2003; Hutchinson et al., 2008a; Zhao
et al., 2012; Sun et al., 2014). The underlying mechanism
remains obscure .Application of exogenous CXCL12 (Heinisch
et al., 2011) and gp120 (Chen et al., 2011b), both of which are
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ligands of CXCR4 receptor, significantly attenuate morphine-
mediated hyperpolarization in rodent periaqueductal grey (PAG)
neurons. Wilson et al. (2011) also suggested that sensory
neurons sensitized by the CXCL12-CXCR4 axis (or the gp120-
CXCR4 axis) may facilitate the hyperalgesia induced by opioids.
Moreover, morphine induces CXCR4-mediated activation of
extracellular signal-regulated kinase (ERK) in rat neurons, a
crucial regulator of peripheral and central sensitization. This may
be one mechanism of gp120/opioid synergism in neuropathic
pain (Ji, 2004; Patel et al., 2006; Sengupta et al., 2009).
GLIAL MECHANISMS
Converging evidence indicates a key role for glia and neuron-glia
interactions in the development and maintenance of neuropathic
pain (Jin et al., 2003; Hansen and Malcangio, 2013; Ji et al., 2013;
Walters, 2014). Glia mediate many of the neurotoxic effects of
HIV-1 and co-exposure of glia to opioids and HIV-1 appears
to exacerbate proinflammatory and excitotoxic events that lead
to neuron dysfunction. Because of these observations, we are
investigating the potential that glia-mediated mechanisms may
contribute to the pathogenesis of neuropathic pain that is caused
by HIV-1 and chronic opioid use.
Glial Activation and Pain
Glial cells, including astrocytes, microglia, and oligodendrocytes,
play important roles in supporting and regulating neuronal
functions (Watkins et al., 2005). The involvement of glia in
neuropathic pain was first suggested in the mid-1990s (Colburn
et al., 1997). Numerous studies have since suggested critical roles
of both microglia (Raghavendra et al., 2003; Tsuda et al., 2003;
Coull et al., 2005; Ji and Suter, 2007) and astrocytes (Meller
et al., 1994; Watkins et al., 1997; Ji et al., 2006; Chiang et al.,
2007, 2012; Guo et al., 2007; Okada-Ogawa et al., 2009; Gao
and Ji, 2010b; Ren and Dubner, 2010) in the pathogenesis of
pathological pain. Activation of astrocytes and microglia can
cause neuroanatomical and neurochemical transformations in
the CNS that contribute to neuropathic pain (Colburn et al.,
1999; Woolf and Mannion, 1999). Malfunctioning astrocytes
and microglia may dysregulate synaptic function and neuronal
excitability by various mechanisms (Halassa et al., 2007; Pocock
and Kettenmann, 2007).
Reactive glia secret proinflammatorycytokines such as tumor
necrosis factor-α(TNF-α), IL-1β, and IL-6 that facilitate the
expression of central sensitization (Seifert and Maihofner, 2011).
Inhibition of the cytokines can effectively reduce neuropathic
pain (Moalem and Tracey, 2006). Cytokines are up-regulated in
the spinal cord after nerve injury, inflammation, bone cancer, and
chronic opioid exposure, and they contribute to the development
and maintenance of various types of chronic pain (DeLeo and
Yezierski, 2001; Sommer et al., 2001; Watkins et al., 2001;
Svensson et al., 2005). For instance, peripheral nerve injury causes
the up-regulation of TNF-α and TNFR1 in DRG and the spinal
dorsal horn (Schafers et al., 2003; Ohtori et al., 2004; Xu et al.,
2006), which facilitates the development of neuropathic pain
(Sommer and Kress, 2004; Wieseler-Frank et al., 2005). Inhibition
of TNF-α inhibits the pain pathogenesis (George et al., 2000;
Ribeiro et al., 2000). IL-1β is induced in the spinal cord in animal
models of bone cancer pain, inflammatory pain, and nerve injury
pain (Zhang et al., 2005; Guo et al., 2007; Wei et al., 2008;
Weyerbacher et al., 2010). Inhibition of spinal IL-1β signaling
with IL-1 receptor antagonist (IL-1ra) or neutralizing antibody
alleviatespain behaviors (Milligan et al., 2001, 2003; Sweitzer
et al., 2001; Guo et al., 2007; Kawasaki et al., 2008b; Wei et al.,
2008; Zhang et al., 2008). Conversely, intrathecal injection of IL-
1βinduces hyperalgesia (Tadano et al., 1999; Reeve et al., 2000; Ji
et al., 2002; Sung et al., 2004; Kawasaki et al., 2008a). Persistent IL-
6 increase after spinal cord injury (SCI) appears to correlate with
the development of chronic pain both in SCI patients (Davies
et al., 2007) and in an animal model of SCI (Detloff et al., 2008).
Furthermore, injection of IL-6 in rats causes hypersensitivity to
thermal and mechanical stimuli (Oka et al., 1995; Poole et al.,
1995; DeLeo et al., 1996; Brenn et al., 2007). Pro-inflammatory
cytokines (TNF-α, IL-1β, and IL-6) have been shown to induce
the trafficking and surface expression of AMPA receptors in
hippocampal neurons (Beattie et al., 2002; Stellwagen et al., 2005),
enhance NMDA currents of spinal lamina II neurons (Kawasaki
et al., 2008b; Gao et al., 2009), and increase the frequency and
amplitude of spontaneous postsynaptic currents (sEPSCs) in
dorsal horn neurons (Kawasaki et al., 2008b). These neuronal
effects of cytokines may directly contribute to the expression of
pathological pain.
Chemokines are a group of cytokines that induce cell
migration (Walz et al., 1987; Yoshimura et al., 1987). Recent
evidence suggests that chemokine signaling contributes to the
pathogenesis of chronic pain by regulating glial activation and
neural plasticity (White et al., 2007; Abbadie et al., 2009; Gao and
Ji, 2010a; Clark et al., 2011). Among them, CCL2 (MCP-1) is one
of the best studied chemokines in pain modulation. It is highly
expressed in astrocytes after spinal nerve ligation (Gao et al.,
2009) and spinal cord contusion injuries (Knerlich-Lukoschus
et al., 2008). Spinal injection of TNF-α-activated astrocytes
results in persistent mechanical allodynia by releasing CCL2 (Gao
et al., 2010). Chemokines may regulate pain transmission by
stimulating specific chemokine receptors such as CCR2, CCR5,
CXCR4, and CX3CR1 that are expressed in primary afferent
neurons or secondary neurons in the spinal dorsal horn (Abbadie
et al., 2003). In spinal cord slices, chemokines were shown to
evoke excitatory postsynaptic currents (EPSCs) from lamina II
neurons (Yoshimura and Jessell, 1989). Addition of CCL2 to
cultured DRG neurons elicits release of calcitonin gene-related
peptide (CGRP), a nociceptor neurotransmitter (White et al.,
2009).
Glia may also regulate pain pathogenesis by modulating
the level of extracellular glutamate, the major excitatory
neurotransmitter. Glial glutamate transporter 1 (GLT-1) is
abundantly expressed in astrocytes (Beart and O’Shea, 2007).
It plays a critical role in clearing extracellular glutamate from
synaptic clefts (Huang and Bergles, 2004; Tawfik et al., 2006)
and hence modulates glutamatergic transmission and neuronal
plasticity (Rothstein et al., 1994, 1996). Inhibition of glutamate
transporters results in elevation of spinal extracellular glutamate
and spontaneous pain (Liaw et al., 2005; Weng et al., 2006).
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Spinal nerve injury induces an initial increase (Sung et al.,
2003; Wang et al., 2008) followed by a persistent decrease
of GLT1 in the spinal cord astrocytes (Tawfik et al., 2008;
Xin et al., 2009). GLT-1 gene delivery to the spinal cord
attenuates inflammatory and neuropathic pain (Maeda et al.,
2008), supporting a critical contribution of glutamate transporter
down-regulation to pain pathogenesis (Sung et al., 2003; Weng
et al., 2005).
The evidence outlined above illustrates that activated glia
may promote pain pathogenesisthrough diverse mechanisms,
including releasing pro-inflammatory cytokines and chemokines
and down-regulating glutamate transporters. Interestingly, as we
will discuss in the next sections, emerging evidence indicates that
HIV-1 infection and chronic opioid use also dysregulate these
pain pathogenic processes.
HIV-1 and Opioids in Glial Activation
Opiate drug abuse and HIV-1 are interlinked epidemics (Bell
et al., 1998; Anthony et al., 2008), and opioids can exacerbate
the neuropathogenesis of HIV-1 (Hauser et al., 2012). In human
HIV-1 patients, opiate drug abuse was reported to increases glial
reactivity in the CNS with specific alterations in the number and
morphology of reactive microglia (Bell et al., 2002). Similarly,
morphine rapidly and significantly increases the activation of
microglia in the brains of Tat transgenic mice. Additionally, both
HIV-1 proteins (e.g., gp120 and Tat) and opioids can activate
astrocytes in the SDH (Milligan et al., 2001; Huang et al., 2012).
Emerging evidence supports a role for the interaction of
opioids and HIV viral proteins in glial activation, although the
underlying mechanisms remain unclear. The interaction depends
on mu-opioid receptors (Zou et al., 2011), which are widely
expressed in astrocytes (Stiene-Martin et al., 1998, 2001) and
microglia (Tomassini et al., 2004). While opioids can directly
cause glial activation (El-Hage et al., 2005, 2006, 2008a,b; Bruce-
Keller et al., 2008; Turchan-Cholewo et al., 2008, 2009; Gupta
et al., 2010), intrastriatal Tat infusion enhanced the activation
of glia in vivo (El-Hage et al., 2006). Morphine analgesics
can activate both classical opioid receptors andthe non-classical
receptor Toll-like receptor 4 (TLR4; Hutchinson et al., 2010b),
which is expressed in glia that are implicated in various chronic
pain syndromes (Hutchinson et al., 2008b, 2010a; Lewis et al.,
2010, 2012). Additional evidence indicates that TLR4 activation
opposes the analgesic effect of morphine (Watkins et al., 2009;
Hutchinson et al., 2010b). The type of opioid receptor that
is involved in the opioid/HIV-1 interaction for pain-related
synergistic activation of glia is unknown.
Intracellular calcium may be a critical mediator in astrocyte
activation that is induced by HIV-1 protein and opioids. Tat or
gp120 can evoke an increase in intracellular Ca2+ ([Ca2+]i) in
astroglia (Haughey et al., 1999; Holden et al., 1999). Similar effects
are also observed after acuteµ-opioid receptor activation (Hauser
et al., 1998). Morphine and HIV-1 viral proteins synergistically
induce Ca2+release from the endoplasmic reticulum (ER) and
Ca2+ influx from extracellular spaces of astrocytes, which
enhance cytokine and chemokine release (El-Hage et al., 2008b).
The increased [Ca2+]i may contribute to the development of
hyperalgesia by regulating synaptic transmission and activity of
NMDA and AMPA receptors in the spinal cord (Meller et al.,
1996; Guo et al., 2007; Chen et al., 2010b). Furthermore, increased
intracellular Ca2+ can also activate Ca2+-sensitive proteins
such as protein kinase C (PKC) and calcium/calmodulin-
dependent protein kinase II (CaMK II; Kuhl et al., 2000), both
of which play crucial roles in central sensitization during the
development of neuropathic and inflammatory pain (Malmberg
et al., 1997; Martin et al., 2001; Chen et al., 2010a). CaMKIIα is
required for the initiation and maintenance of opioid-induced
hyperalgesia (Chen et al., 2010a). Together, these findings
indicate that enhanced intracellular Ca2+ might be vital for
astrocyte activation during pain development. Opioids may
synergize with HIV viral proteins in these processes in glial cells.
As a result, normally neuroprotective glia (Kaul et al., 2001)
and mononuclear phagocytes (Persidsky and Gendelman, 2003)
are functionally transformed into deleterious states thatdisrupt
CNS homeostasis and create pathophysiological conditions that
induce in juries in pain-processing neurons.
Interactions of Opioids and HIV-1 in
Neuropathic Pain
Findings such as those summarized above indicate that the
interactions of HIV-1 and opioids have a synergistic effect
on glial activation. Since glial activation plays a key role in
neuropathic pain development, we reason that HIV-1 infection
and opioids interact to promote pain pathogenesis. Several
pathogenic pathways can be envisioned to mediate the synergistic
effect of opioids and HIV-1 proteins in this scenario.
One of the potential mechanisms is probably mediated by the
enhanced pro-inflammatory cytokine release from activated glia.
Glial cells are the major source of cytokines (e.g., TNF-α, IL-
1β, and IL-6) in the HIV-1-infected CNS (Dong and Benveniste,
2001; Luo et al., 2003). Opioids exacerbate the glial response
to HIV-1by accelerating cytokine release (El-Hage et al., 2005).
Additionally, HIV replication in microglia can be stimulated by
opioids, which leads to the release of toxic viral proteins that
then stimulate the release of inflammatory toxins (Glass et al.,
1995; Nath et al., 1999; Yadav and Collman, 2009). Opioids may
directly activate MOR on microglia (Bruce-Keller et al., 2008; El-
Hage et al., 2008a; Turchan-Cholewo et al., 2008, 2009; Gupta
et al., 2010) to evoke cytokine and reactive/oxidative responses
to insults (Wetzel et al., 2000; Rahim et al., 2003; Qin et al.,
2005; Wang et al., 2005). NF-κB is involved in the induction of
cytokines in glia (Zhai et al., 2004). HIV-1 Tat activates NF-κB
(Conant et al., 1996; El-Hage et al., 2008a) to cause the release
of a large amount of cytokines by glia (Conant et al., 1998;
El-Hage et al., 2005, 2006, 2008a). Pro-inflammatory cytokines
could facilitate the development of hyperalgesia by regulating the
activity of synaptic receptors such as NMDARs and AMPARs
(Meller et al., 1996; Guo et al., 2007; Chen et al., 2010b).
For instance, IL-1β, IL-6, and TNF-α can enhance excitatory
synaptic transmission and increased density and conductance
of neuronal AMPA (Ogoshi et al., 2005; Stellwagen et al., 2005)
and NMDA (Viviani et al., 2003) receptors, and these cytokines
can down-regulate neuronal GABA receptors (Stellwagen et al.,
2005).
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Glia are also a major source of chemokines (e.g., CCL2/MCP-
1, CCL5/RANTES, and CCL3/MIP-1a) in the HIV-1-infected
CNS (Dong and Benveniste, 2001; Luo et al., 2003). The
contribution of chemokines to pain pathogenesis is well
established (Liou et al., 2013). Opioids exacerbate the astroglial
response to HIV-1and stimulate release of chemokines (El-
Hage et al., 2005). NF-κB signaling is also implicated in
chemokine induction in astrocytes (Zhai et al., 2004). HIV-
1Tat activates NF-κB (Conant et al., 1996; El-Hage et al.,
2008a) to elicit release of many chemokines from astroglia
(Conant et al., 1998; El-Hage et al., 2005, 2006, 2008a).
Previous studies observed synergistic effects of HIV-1 viral
proteins and opiate agonists on chemokine release from glia
(El-Hage et al., 2006). Similar to the cytokines discussed above,
chemokines may also promote the development of hyperalgesia
by regulating synaptic transmission and activity of NMDA and
AMPA receptors (Meller et al., 1996; Guo et al., 2007; Chen
et al., 2010b). Since specific chemokine receptors such as CCR2,
CCR5, CXCR4, and CX3CR1 are expressed in primary afferents
and/or secondary neurons in the spinal dorsal horn (Oh et al.,
2001; Abbadie, 2005), chemokines may modulate pain signal
transmission.
Another potential mechanism by which opioids and HIV-1
may cooperate to dysregulate pain-related glial function is to
down-regulate their glutamate re-uptake activity. Under normal
physiologic conditions, extracellular glutamate is rapidly cleaned
by re-uptake processes mediated by glutamate transporters
EAAT1 (a.k.a. GLAST) and EAAT2 (a.k.a. GLT-1). EAAT1 and
EAAT2 are predominantly expressed by astroglia (but only
have low expression in microglia; Gras et al., 2006, 2012).
Chronic morphine administration induces down-regulation
of spinal glutamate transporters (Ozawa et al., 2001; Mao
et al., 2002b). Interestingly, a decrease of EAAT2 expression
was also observed in human astrocytes exposed to gp120
or HIV-1 (Wang et al., 2003). Exposure to morphine and
HIV-1 Tat boosts extracellular glutamate accumulation at the
synapse (Madl and Burgesser, 1993; Phillis et al., 2000),
which is expected to cause excitotoxicity (Albrecht et al.,
2010).
The above findings indicate that opioids and HIV-1 interact
to activate glia, leading to enhanced cytokine and chemokine
expression (Mahajan et al., 2005) and down-regulation of
glutamate uptake (Zou et al., 2011). These biological effects
are detrimental to neurons and may directly contribute to the
development of hyperalgesia.
SUMMARY
Opioid abuse and HIV-1 have been described as interrelated
epidemics, and they can exacerbate the neuropathogenesis
of neuroAIDS (Hauser et al., 2012). Here, we have mainly
considered the potential mechanisms by which the interaction of
opioids and HIV-1 facilitates the development of hyperalgesia.
Because mounting evidence suggests that they have synergistic
effects on neurons and glia, we are working to understand
the pathogenic processes from the perspectives of these cell
types and their interactions. Based on the previously findings
discussed earlier, we suggest that HIV-1 and opioids dysregulate
the function of neurons and glia in the pain-processing neural
pathway. The ongoing reactive cross-talk between opiate drugs
and HIV-1 may not only directly injure pain-transmission
neurons but also indirectly contribute to the injuries by activating
glia, especially microglia and astrocytes.
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